With the mid-year reinsurance renewals disappointing underwriters and investors alike, attention is now focused on primary insurers for signs that the much heralded turn in US commercial pricing is made of stronger stuff.
With the mid-year reinsurance renewals disappointing underwriters and investors alike, attention is now focused on primary insurers for signs that the much heralded turn in US commercial pricing is made of stronger stuff.